INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow Shareholders, As we reflect on 2025, ...

Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categoriesReader ...

Shiong, ImmunityBio Inc., and its leaders have defeated a shareholder challenge to a financing arrangement amid pending ...

Biology software developer Phylo Inc. today announced that it has raised $13.5 million in seed funding. Andreessen Horowitz ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at ...

To learn more about Imbed Biosciences and its innovative wound care technologies, please visit "The strategic investment from BioLab Holdings marks a pivotal moment for Imbed Biosciences," said Terry ...

A financing arrangement between biotech billionaire Dr. Patrick Soon-Shiong and ImmunityBio Inc. helped “bridge the gap” to ...

The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab ...

AskBio Inc., an RTP-based gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, has received U.S. Food and Drug Administration (FDA) acceptance of its ...

Aimed Bio, Inc. operates as a biotechnology company. It engages in the development of anticancer drugs based on antibody-drug conjugates (ADCs). The company was founded by Do-Hyun Nam on August 27, ...